equitysell

IGF

Trust-weighted public proof page for IGF. See which authors support it, which ticker theses it belongs to, and how thesis calls have performed.

Opportunity
35 / 100
Current score
-0.60
Thesis calls
1
Active ticker theses
1

Recent proof-backed thesis calls

Public preview of asset-level thesis calls linked to source content, observed prices, and outcomes.

Content discusses human endocrinology (GH/LH/IGF-1, insulin, Leydig cell sensitivity, HPG axis) and makes no explicit market, company, sector, macro, or investable-asset claims. Not directly translatable into a tradable catalyst without additional context (e.g., drug/company linkage, clinical results, regulation, product demand).

Mentioned: Jul 24, 2026, 10:32 AM EDTConviction: 60 / 100Observed price: $67.66 on 2026-07-24Return: -1.58%
Source: _aestheticprimal_ @aestheticprimal 29m GH follows the same pattern as LH, in the way it rises in effort of overcompen...

Latest market-close explanation

2026-07-24unavailable

No market-close explanation is available for `IGF` on 2026-07-24 because usable price history was not available. Reason: no_market_data.

Current stance

Recommendationsell
Authors1
Active ticker theses1
Latest pricen/a
Why now
  • sell via AI demand pressures GH-led basket from https://x.com/aestheticprimal (confidence 0.60)

Unlock full asset monitoring

Create an account to access full asset history, alerts, Telegram workflows, and trust-weighted live rankings across authors, ticker theses, and market events.